Going big in Britain

How Syncona, BACIT and CRT Pioneer Fund plan to aggressively build U.K. biotechs

After combining with two cancer-focused funds, U.K. VC Syncona Partners expects to have enough firepower to take an aggressive company-building approach more typical of its U.S. counterparts.

Under a deal proposed Nov. 7, BACIT Ltd. (LSE:BACT) would acquire Syncona and Cancer Research Technology

Read the full 434 word article

User Sign In